Related Experiment Video
Updated: Mar 27, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Ketogenic diet effects on neurobehavioral development of children with intractable epilepsy: A prospective study
Dengna Zhu1, Mingmei Wang1, Jun Wang1
1Cerebral Palsy Rehabil. Dept., Zhengzhou Univ., Affiliated Hosp 3, Zhengzhou 450052, Henan, PR China.
Insights
The ketogenic diet (KD) improves neurobehavioral development in children with intractable epilepsy. Early EEG changes predict treatment success, showing KD is safe and effective.
Area of Science:
- Pediatric Neurology
- Neurodevelopmental Disorders
- Dietary Therapies
Background:
- Intractable epilepsy in children poses significant challenges to neurodevelopment.
- The ketogenic diet (KD) is a recognized therapy for drug-resistant epilepsy.
- Understanding KD's impact on neurobehavioral development is crucial.
Purpose of the Study:
- To assess the effect of the ketogenic diet (KD) on neurobehavioral development in children with intractable epilepsy.
- To confirm the efficacy of KD in this patient population.
- To explore the correlation between early electroencephalography (EEG) changes and treatment outcomes.
Main Methods:
- 42 children with intractable epilepsy initiated the classic KD protocol.
- Gesell developmental scales assessed neurobehavioral quotients (adaptability, motor skills, social interaction) at baseline and 18 months.
- Seizure frequency reduction and 24-h video-EEG changes were monitored.
Main Results:
- Significant improvements observed in adaptability, gross motor, and fine motor development quotients.
- Seizure frequency reduction of ≥50% achieved by 69.0% of patients at 3 months, decreasing over time.
- Reduced epileptiform discharges on EEG after 1 month correlated with 3-month seizure control.
Conclusions:
- Ketogenic diet (KD) treatment is associated with improved neurobehavioral development in children with intractable epilepsy.
- Prolonged KD treatment yields greater developmental benefits.
- KD is a safe and effective epilepsy therapy, with early EEG changes indicating potential efficacy.
Objective:
This study aimed to determine the impact of a ketogenic diet (KD) on neurobehavioral development when used to treat children with intractable epilepsy, confirming the efficacy of the KD, as well as the correlation between early electroencephalography (EEG) changes in the early stage with treatment efficacy.
Methods:
We enrolled 42 children who were starting treatment for intractable epilepsy with the classic KD protocol. The total development quotient as well as the development quotients for adaptability, gross motor movements, fine motor movements, language, and individual-social interaction on the Gesell developmental scales were assessed before and after 3, 6, 12, and 18 months of KD treatment. The efficacy assessment was based on changes in seizure frequency after KD as recorded by the parents. We conducted 24-h video-EEG before and after 1 month of KD treatment.
Results:
Developmental quotients of five energy regions in the Gesell developmental scales assessment were used to compare adaptability (P1=0.000), gross motor movements (P2=0.010), and fine motor movements (P3=0.000); the results showed significant differences. After KD treatment at different time points, 69.0%, 54.8%, 40.5%, and 33.3% patients, respectively, achieved a ≥50% reduction in seizure frequency. The reduction of epileptiform discharges in the awake state after 1 month of KD treatment correlated with the efficacy after 3 months of KD treatment.
Conclusions:
Ketogenic diet treatment tends to be associated with improved neurobehavioral development, and more significant improvement can be obtained with prolonged treatment. The KD is safe and effective in treating children with intractable epilepsy. Early EEG changes correlate with clinical efficacy, to a certain degree.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Electroconvulsive Therapy

